ACE2 and COVID-19: Administration of microRNA 200c inhibits both ACE2 mRNA and ACE2 protein levels in human iPSC-derived cardiomyocytes and primary cardiomyocytes of COVID-19 rat model, which is a potential regimen for cardiovascular complications of COVID-19.411 Besides, excessive ACE2 may competitively bind with SARS-CoV-2, thereby neutralizing the virus and rescuing cellular ACE2 activity which negatively regulates the RAS to protect the lung.410,412,413 Therefore, treatment with a soluble form of ACE2 may be effective against SARS-CoV-2 infection.